CD14 and metabolic dysfunction-associated steatotic liver disease: The number of circulating EVs from invariant natural killer cells and CD14+ monocytes/macrophages differentiated patients with NAFLD (n = 67) from patients with hepatitis C (n = 42) and healthy controls (n = 44) and may represent a novel diagnostic tool for not only separating NAFLD patients from healthy individuals, but also differentiating between various chronic liver diseases [64].